Projecting future drug expenditures - 2000

American Journal of Health-System Pharmacy

Volumn 57, Issue 2, 2000, Pages 129-138

  Mehl, Bernard ^a   Santell, John P ^b  

^a MOUNT SINAI HOSPITAL   (United States)

^b AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS   (United States)

Author keywords

Costs; Drug use; Economics; Health care; Internet; Pharmacy, institutional; Regulations; Technology

Indexed keywords

GENERIC DRUG;

DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL PURCHASING; INTERNET; MEDICARE; OUTPATIENT CARE; PHARMACOGENOMICS; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE PRICING; REVIEW;

EID: 0034650623     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.2.129     Document Type: Review

References (50)

1. Health Care Financing Administration. National health expenditures projections: 1998-2000. www.hcfa.gov/stats/nhe-proj/ proj1998/hilites.htm (accessed 1999 Jul 22).
2. IMS recounts manufacturer prescription sales top $100 billion mark. Drug Top. 1999; 143(9):15.
3. Ringold DJ, Santell JP, Schneider PJ et al. ASHP national survey of pharmacy practice in acute care settings: prescribing and transcribing - 1998. Am J Health-Syst Pharm. 1999; 56:142-57.
4. Lazarus H. The Lazarus report, 1998. Birmingham, AL; 1999 Apr.
5. Drug prices edging upward again. Hosp Mater Manage. 1999; 24(5):1.
6. Prescription drug sales expected to climb 43% in the US by 2002. Wall St J. 1999; Jun 8:B-14.
7. Davis M, Poisal J, Chulis G et al. Prescription drug coverage, utilization, and spending among Medicare beneficiaries. Health Aff. 1999; Jan/Feb:231-43.
8. Chain Rx volume to grow at double rate of mail-order in'99 - NACDS. FDC Rep. 1999; 61(Scp 6):19.
9. Even without Aetna merger, consumers are losing choice. USA Today. 1999; Jun 28:15A.
10. Medicare could pay $92 billion for drugs in 2008 at highest subsidy level. FDC Rep. 1999; 61(Jul 5):3.
11. Calfee JE. Price controls are a prescription for disaster. Wall St J. 1999; Jul 22:A-26.
12. Mehl B, Santell JP. Projecting future drug expenditures - 1999. Am J Health-Syst Pharm. 1999; 56:31-9.
13. Mehl B, Santell JP. Projecting future drug expenditures-1998. Am J Health-Syst Pharm. 1998; 55:127-35.
14. Mehl B, Santell JP. Projecting future drug expenditures - 1997. Am J Health-Syst Pharm. 1997; 54:153-61.
15. Santell JP. Projecting future drug expenditures - 1996. Am J Health Syst Pharm. 1996; 53:139-50.
16. Santell JP. Projecting future drug expenditures - 1995. Am J Health-Syst Pharm. 1995; 52:151-63.
17. Santell JP. Projecting future drug expenditures - 1994. Am J Hasp Pharm. 1994; 51:177-87.
18. Santell JP. Projecting future drug expenditures - 1993. Am J Hosp Pharm. 1993; 50:71-7.
19. Ensor PA. Projecting future drug expenditures - 1992. Am J Hosp Pharm. 1992; 49:140-5.
20. Engel S. Best pipelines. R&D Dir. 1998; 5(1):36-96.
21. Engel S. Pressures on the pipeline. R&D Dir. 1999; 5(4):3.
22. Engel S. The pipeline is full. R&D Dir. 1999; 5(6):3-6.
23. Myshko D. The best pipelines. R&D Dir. 1998;4(1):24-7.
24. Eichenwald K, Kolata G. Drug trials hide conflicts for doctors. N Y Times. 1999; May 16:A-1,A-35-6.
25. Eichenwald K, Kolata G. Doctor's drug studies turn into fraud. N Y Times. 1999; May 17:A-1,A-16-7.
26. Eichenwald K. US officials are examining clinical trials. N Y Times. 1999; Jul 14:C-1,C-10.
27. Pristin T. Alliance formed to draw money for testing drugs. N Y Times. 1999; Jan 17:A-37.
28. Schwartz RM. FDA speeds up approvals. Am Drug. 1999; 216(Feb):16.
29. Stolberg SG. Drug review is effective, agency says. Wall St J. 1999; May 11:A-16.
30. Burton TM, Sharpe R. Sales of Monsanto's Celebrex drop sharply in recent reports. Wall St J. 1999; Apr 28:B-2.
31. Judge overturns law that limits release of drug-use information. N Y Times. 1999; Jul 29:A-18.
32. Carey J. This drug's for you. Bus Week 1999; 3612(3):98-100.
33. Flockhart D, Webb DJ. Blue-chip technology. Lancet. 1998; 352(suppl 4):2.
34. Langreth C. Drugs based on genetics enter human trials. N Y Times. 1999; Mar 26:B-1,B-4.
35. Beyond genomics. R&D Dir. 1999; 5(4):40-4.
36. Burton TM. Why generic drugs often can't compete against brand names. Wall Str J. 1998; Nov 18:A-1.
37. Latner AW. 1999 generic drug annual report. Pharm Times Suppl. 1999; Feb:6.
38. As some generic prices soar, RPhs are crying foul. Drug Top. 1998; 143(5):23.
39. King RT. FTC widens probe into generic drug barriers. N Y Times. 1999; Mar9:B1,B3.
40. Fair play or foul? Drug Top. 1999; Apr 5:15.
41. O'Donnell J. Cancer drug probe picks up. USA Today. 1999; Jun 28:B-1.
42. Generic drug label reference to brand product is legally allowed, FDA says. FDC Rep. 1999;61(Feb 1):32.
43. Sharpe R. FDA tries to find right balance on drug approvals. Wall St J. 1999; Apr 20:D-24.
44. GAO to review online pharmacies. Health Data Manag. 1999; May:18.
45. NABP maps plans to verify Internet pharmacy licenses. Drug Top. 1999; 143(5):7.
46. Tanouye E. Web links give drug reps foot into doctors' door. N Y Times. 1999; May 18:B1-3.
47. Express Scripts full-service Internet pharmacy will open in second quarter. Green Sheet. 1999; 49(14):1.
48. Internet pharmacies join PCMA; CVS.com joins Internet race. Green Sheet. 1999; 49(19):1.
49. Health expenses rise, but more gently. Managed Care. 1999; Aug:13.
50. Rosenbaum RE. The gathering storm over prescription drugs. NY Times. 1999; Nov 14:Sec 4-1,16.